China Diagnostic Reagent Company Goes Global
This article was originally published in PharmAsia News
Executive Summary
Shanghai Kehua Bio-engineering Co., Ltd., a major diagnostic reagent manufacturer in China, announced that its 42 diagnostic reagents and three medical devices have received the CE marking, which means it can enter the EU market. The company will be setting up a joint venture with leading diagnostic equipment manufacturer Bio Merieux. The worldwide diagnostic reagent business is worth $20 billion, and the 4-billion-yuan China market is expected to grow at 15-20 percent annually over the next five years. The business potential is attracting MNCs, which will intensify the competition for local players greatly limited by size, product varieties and poor development. (Click here for more - Chinese Language)
You may also be interested in...
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.